Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Tyche Industries has informed that, the United States Food & Drug Administration (USFDA) completed inspection of its manufacturing facility situated at Kakinada, Andhra Pradesh during August, 2024 and issued Seven observations. Further informed that United States Food & Drug Administration (USFDA) has classified the inspection as ‘Official Action Indicated’ (OAI). The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis. The company will work with the USFDA to resolve these issues at the earliest.
The above information is a part of company’s filings submitted to BSE.
